Janus kinase inhibitors: a future all-rounder in axial spondyloarthritis?

Therapeutic potential of JAK inhibitors in juvenile idiopathic arthritis-associated uveitis

(2023) Ilaria Maccora et al.   Expert Review of Clinical Immunology

Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis

(2023) Gerd R Burmester et al.   RMD Open

Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross‐sectional observational study

(2022) Sang‐Hoon Lee et al.   International Journal of Rheumatic Diseases

Intermediate Uveitis in an HLA-B27-Positive Patient Treated with Upadacitinib

(2022) Julie Schneider et al.   KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE

Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial

(2022) Désirée van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

Comparative safety of Janus kinase inhibitors and tumor necrosis factor inhibitors in patients undergoing treatment for rheumatoid arthritis

(2022) Yao‐Fan Fang et al.   International Journal of Rheumatic Diseases

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2022) Atul Deodhar et al.   LANCET

New and updated recommendations for the treatment of juvenile idiopathic arthritis associated uveitis and idiopathic chronic anterior uveitis

(2022) Ivan Foeldvari et al.   ARTHRITIS CARE & RESEARCH

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension

(2022) Désirée van der Heijde et al.   RMD Open

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update

(2022) Sofia Ramiro et al.   ANNALS OF THE RHEUMATIC DISEASES

Are Janus kinase inhibitors safe and effective in treating the key clinical domains of psoriatic arthritis? A systematic review and meta‐analysis

(2022) Patricia Harkins et al.   International Journal of Rheumatic Diseases

Ophthalmic adverse events under tofacitinib and baricitinib: Case analysis of the European Pharmacovigilance Database

(2022) Sophie Hecquet et al.   JOINT BONE SPINE

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study

(2021) Atul Deodhar et al.   ANNALS OF THE RHEUMATIC DISEASES

Upadacitinib in Active Ankylosing Spondylitis: 1‐Year Results From the Double‐Blind, Placebo‐Controlled SELECT‐AXIS 1 Study and Open‐Label Extension

(2021) Atul Deodhar et al.   Arthritis & Rheumatology

Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis

(2021) Juan S Lasa et al.   Lancet Gastroenterology & Hepatology

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease

(2020) William J. Sandborn et al.   GASTROENTEROLOGY

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

(2019) Désirée van der Heijde et al.   LANCET

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial

(2018) Désirée van der Heijde et al.   LANCET